Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Leukostimulatory Activity of the Preparation Panagen in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated written informed consent~* Women at an age of ≥18 years~* Stage II-IV breast cancer (with distant metastases)~* The patients will be subject to chemotherapy with cyclophosphan/doxorubicin/ fluorouracil as a standard chemotherapy for treating breast cancer~* The patients have not been earlier subject to chemotherapy~* Functional status according to the Eastern Cooperative Oncology Group (ECOG) ≤2~* Leukocyte counts of ≥3 × 109/L before the treatment course~* Neutrophil counts of ≥1.5 × 109/L before the treatment course~* Platelet counts of ≥100 × 109/L before the treatment course~* Adequate heart function~* Adequate liver function, that is, alanine aminotransferase / aspartate aminotransferase (ALT / AST) activity \< 2.5 × upper limit of normal (ULN); acid phosphatase activity \< 5 × ULN; and bilirubin concentration \< 5 × ULN; and~* Adequate renal function, that is, the creatinine concentration in the blood serum \< 1.5 × ULN; urea concentration \< ULN; and endogenous creatinine clearance~Exclusion Criteria:~* Participation in clinical trials less than 30 days before sequential randomization~* Previous exposure to Panagen or any other leukostimulatory drugs at a stage of clinical development~* Known hypersensitivity to cyclophosphan, doxorubicin, or fluorouracil~* Therapy with systemically active antibiotics less than 72 h before the beginning of chemotherapy~* Long-term oral intake of corticosteroids~* Previous X-ray therapy performed less than 4 weeks before randomization~* Previous transplantation of hematopoietic stem cells~* Other malignant neoplasms during the last 5 years except for basal cell or flat cell carcinoma or intraepithelial carcinoma of the uterine cervix~* Any disease or state that according to the opinion of researcher can influence patient's safety or the estimation of a final trial point; and~* Pregnant and nursing women; the fertile patients should use chemical or barrier contraceptives during the period of trials

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy & Panagen (Type: EXPERIMENTAL): Panagen 5 mg tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the preparation immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).
- Chemotherapy & Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the placebo tablets immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).

Based on this trial design, predict the completion outcome and termination type (if applicable).